BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32007535)

  • 1. Regional Variation in Appropriateness of Non-Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception.
    Cannon RM; Davis EG; Goldberg DS; Lynch RJ; Shah MB; Locke JE; McMasters KM; Jones CM
    J Am Coll Surg; 2020 Apr; 230(4):503-512.e8. PubMed ID: 32007535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.
    Goldberg D; French B; Abt P; Feng S; Cameron AM
    Liver Transpl; 2012 Apr; 18(4):434-43. PubMed ID: 22271656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Center variation in the use of nonstandardized model for end-stage liver disease exception points.
    Goldberg DS; Makar G; Bittermann T; French B
    Liver Transpl; 2013 Dec; 19(12):1330-42. PubMed ID: 24039090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation.
    Northup PG; Intagliata NM; Shah NL; Pelletier SJ; Berg CL; Argo CK
    Hepatology; 2015 Jan; 61(1):285-91. PubMed ID: 24995689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival.
    Mehta N; Dodge JL; Roberts JP; Yao FY
    J Hepatol; 2021 Apr; 74(4):829-837. PubMed ID: 33188904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma.
    Marvin MR; Ferguson N; Cannon RM; Jones CM; Brock GN
    Liver Transpl; 2015 May; 21(5):612-22. PubMed ID: 25694099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing Liver Transplantation Wait-List Dropout for Hepatocellular Carcinoma With Widening Geographical Disparities: Implications for Organ Allocation.
    Mehta N; Dodge JL; Hirose R; Roberts JP; Yao FY
    Liver Transpl; 2018 Oct; 24(10):1346-1356. PubMed ID: 30067889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system.
    Piscaglia F; Camaggi V; Ravaioli M; Grazi GL; Zanello M; Leoni S; Ballardini G; Cavrini G; Pinna AD; Bolondi L
    Liver Transpl; 2007 Jun; 13(6):857-66. PubMed ID: 17539006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Mandatory 6-Month Waiting Period on Waitlist and Transplant Outcomes in Patients With Hepatocellular Carcinoma.
    Nagai S; Kitajima T; Yeddula S; Salgia R; Schilke R; Abouljoud MS; Moonka D
    Hepatology; 2020 Dec; 72(6):2051-2062. PubMed ID: 32157711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of major hepatocellular carcinoma policy changes on liver transplantation for hepatocellular carcinoma in the United States.
    Shah RH; Chyou D; Goldberg DS
    Liver Transpl; 2022 Dec; 28(12):1857-1864. PubMed ID: 35585774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prioritization for liver transplantation using the MELD score in Chile: Inequities generated by MELD exceptions.: A collaboration between the Chilean Liver Transplant Programs, the Public Health Institute and the National Transplant Coordinator.
    Díaz LA; Norero B; Lara B; Robles C; Elgueta S; Humeres R; Poniachik J; Silva G; Wolff R; Innocenti F; Rojas JL; Zapata R; Hunter B; Álvarez S; Cancino A; Ibarra J; Rius M; González S; Calabrán L; Pérez RM
    Ann Hepatol; 2019; 18(2):325-330. PubMed ID: 31010794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver Transplant Waitlist Outcomes and the Allocation of Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception Points at a Low-Volume Center.
    Tan EK; Goh BKP; Lee SY; Krishnamoorthy TL; Tan CK; Jeyaraj PR
    Transplant Proc; 2018 Dec; 50(10):3564-3570. PubMed ID: 30577239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.
    Young K; Aguilar M; Gish R; Younossi Z; Saab S; Bhuket T; Liu B; Ahmed A; Wong RJ
    Liver Transpl; 2016 Oct; 22(10):1356-66. PubMed ID: 27348270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list.
    Toso C; Dupuis-Lozeron E; Majno P; Berney T; Kneteman NM; Perneger T; Morel P; Mentha G; Combescure C
    Hepatology; 2012 Jul; 56(1):149-56. PubMed ID: 22271250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MELD Exceptions and Rates of Waiting List Outcomes.
    Massie AB; Caffo B; Gentry SE; Hall EC; Axelrod DA; Lentine KL; Schnitzler MA; Gheorghian A; Salvalaggio PR; Segev DL
    Am J Transplant; 2011 Nov; 11(11):2362-71. PubMed ID: 21920019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver transplantation and waitlist mortality for HCC and non-HCC candidates following the 2015 HCC exception policy change.
    Ishaque T; Massie AB; Bowring MG; Haugen CE; Ruck JM; Halpern SE; Waldram MM; Henderson ML; Garonzik Wang JM; Cameron AM; Philosophe B; Ottmann S; Rositch AF; Segev DL
    Am J Transplant; 2019 Feb; 19(2):564-572. PubMed ID: 30312530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of a dropout assessment model of candidates with/without hepatocellular carcinoma on a common liver transplant waiting list.
    Toso C; Majno P; Berney T; Morel P; Mentha G; Combescure C
    Transpl Int; 2014 Jul; 27(7):686-95. PubMed ID: 24649861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Liver Transplant-Related Survival Benefit in Patients With Versus Without Hepatocellular Carcinoma in the United States.
    Berry K; Ioannou GN
    Gastroenterology; 2015 Sep; 149(3):669-80; quiz e15-6. PubMed ID: 26021233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for liver transplant waitlist dropout in patients with hepatocellular carcinoma.
    Park SJ; Freise CE; Hirose R; Kerlan RK; Yao FY; Roberts JP; Vagefi PA
    Clin Transplant; 2012; 26(4):E359-64. PubMed ID: 22693962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver transplantation in the MELD era: a single-center experience.
    Sachdev M; Hernandez JL; Sharma P; Douglas DD; Byrne T; Harrison ME; Mulligan D; Moss A; Reddy K; Vargas HE; Rakela J; Balan V
    Dig Dis Sci; 2006 Jun; 51(6):1070-8. PubMed ID: 16865573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.